Dechra Pharmaceuticals PLC
LSE:DPH

Watchlist Manager
Dechra Pharmaceuticals PLC Logo
Dechra Pharmaceuticals PLC
LSE:DPH
Watchlist
Price: 3 866 GBX Market Closed
Market Cap: 440.4B GBX
Have any thoughts about
Dechra Pharmaceuticals PLC?
Write Note

Dechra Pharmaceuticals PLC
Net Issuance of Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Dechra Pharmaceuticals PLC
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Dechra Pharmaceuticals PLC
LSE:DPH
Net Issuance of Common Stock
ÂŁ181.9m
CAGR 3-Years
11%
CAGR 5-Years
12%
CAGR 10-Years
71%
GlaxoSmithKline PLC
LSE:GSK
Net Issuance of Common Stock
ÂŁ20m
CAGR 3-Years
-3%
CAGR 5-Years
-25%
CAGR 10-Years
N/A
AstraZeneca PLC
LSE:AZN
Net Issuance of Common Stock
$36m
CAGR 3-Years
6%
CAGR 5-Years
-60%
CAGR 10-Years
-23%
Verona Pharma PLC
NASDAQ:VRNA
Net Issuance of Common Stock
$4.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Indivior PLC
LSE:INDV
Net Issuance of Common Stock
-$89m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Dechra Pharmaceuticals PLC
Glance View

Market Cap
440.4B GBX
Industry
Pharmaceuticals

Dechra Pharmaceuticals PLC has carved out its niche in the veterinary pharmaceuticals industry, focusing on animal health, which is a sector often less spotlighted than its human counterpart but equally vital. Established in 1997 and headquartered in Northwich, Cheshire, England, Dechra has steadily made a name for itself as a formidable player addressing veterinary needs through innovative solutions and a dedication to expanding its product range. This company has built its empire by developing, manufacturing, and selling high-quality products that cater to the health of both companion animals, such as dogs and cats, and livestock. They have embedded themselves deeply into the global market, with a presence in countries across Europe, North America, and other regions, addressing therapeutic areas like endocrinology, dermatology, and anesthetics. A significant proportion of Dechra’s revenue comes through their strong partnerships and customer base spread across various veterinary practices and pet owners who rely on their trusted brands like Vetoryl and Felimazole. The company’s business model is finely tuned with a blend of regular product launches and strategic acquisitions, creating a comprehensive portfolio that keeps them ahead in the innovation curve. Not only do they supply medicine, but Dechra also invests heavily in research and development to ensure their offerings remain at the forefront of veterinary medicine. Through this, they balance between organic growth and strategic acquisitions, effectively broadening their impact in the field. This approach has not only propelled their financial success but also underscored their commitment to enhancing the welfare of animals globally.

DPH Intrinsic Value
58.32 GBX
Overvaluation 98%
Intrinsic Value
Price

See Also

What is Dechra Pharmaceuticals PLC's Net Issuance of Common Stock?
Net Issuance of Common Stock
181.9m GBP

Based on the financial report for Jun 30, 2023, Dechra Pharmaceuticals PLC's Net Issuance of Common Stock amounts to 181.9m GBP.

What is Dechra Pharmaceuticals PLC's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 10Y
71%

Over the last year, the Net Issuance of Common Stock growth was 7 809%. The average annual Net Issuance of Common Stock growth rates for Dechra Pharmaceuticals PLC have been 11% over the past three years , 12% over the past five years , and 71% over the past ten years .

Back to Top